Studies of pembrolizumab have shown promising antitumor activity across a wide cohort of patients with clear cell renal cell carcinoma (ccRCC). The results of a recent study, named…
According to findings in an extended follow-up of the ongoing CheckMate 214 trial, nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated…
A study composed of patients from across the USA and Europe observed improved outcomes in those treated with both ilixadencel and sunitinib compared with sunitinib alone. here.
A study completed by researchers in China, of patients with renal cell carcinoma (RCC), attempted to both validate previous conclusions and look at the influencing factors of perioperative renal…
A new analysis published in European Urology suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping…
Authors of an article published in Clinical Genitourinary Cancer analyzed aspects of laparoscopic treatment of renal cell cancer during pregnancy. Led by Lucio Dell’Atti of the Department of…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…